Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057

SHIRE PLC (SHP)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Shire Plc. : arGEN-X enters into a therapeutic antibody alliance with Shire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/29/2012 | 11:01am CET

Rotterdam, the Netherlands and Ghent, Belgium February 29, 2012- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.

Using its cutting edge SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has identified and that are known to contribute to the pathophysiology of severe, rare genetic diseases. arGEN-X will also bring its state-of-the-art antibody capabilities to the collaboration for the preclinical characterization of therapeutic leads. Shire has the option to license the most promising leads for further preclinical and clinical development and commercialization worldwide.

Under the terms of the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments. In return for its option to develop and commercialize products on an exclusive basis, Shire will pay fees, milestones and royalties on product sales. Specific details of the financial terms were not disclosed.

Tim Van Hauwermeiren, CEO of arGEN-X, said, "We are delighted to pioneer human antibodies as novel, first-in-class therapies for rare diseases with a partner of Shire's calibre. Shire's depth of experience in protein-based therapies is the perfect complement to our own discovery capabilities. We are confident that our SIMPLE Antibody™ platform, which consistently delivers antibodies of therapeutic quality against complex targets often intractable with other technologies, will bring significant value to this alliance. We believe this alliance represents an industry first and we are looking forward to an exciting and productive collaboration with Shire."

"As a leader in innovative therapies for rare diseases, Shire is continuing to apply new technologies to address the needs of patients," said Philip J. Vickers, Senior Vice President, Research and Development, Shire Human Genetic Therapies (HGT). "Monoclonal antibody therapy is an underutilized approach to the treatment of rare diseases, and this novel platform has the potential to bring multiple drug candidates into our early-stage pipeline. Partnerships such as this one with arGEN-X are an important part of our strategy to bring new therapies to those suffering from rare diseases worldwide."

About arGEN-X- www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging the power of its broadly applicable, proprietary SIMPLE Antibody™ platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins. The superior choice that arGEN-X brings to antibody discovery enables it to prioritise leads with best-in-class therapeutic properties, thereby increasing the probability of development success. Antibody leads generated from the SIMPLE Antibody™ platform have outstanding physicochemical properties and consistent manufacturability, enabling a seamless transition from discovery into development. arGEN-X has validated its technology on multiple diverse classes of target to date and has successfully delivered in its collaboration with Eli Lilly & Co..

arGEN-X' SIMPLE Antibody™ platform is based on the active immunization of Camelids with target antigens to deliver antibody variable regions that are essentially identical to those of human antibodies. arGEN-X is able to generate full size, human therapeutic antibodies by combining these variable regions with human constant domains.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands forSuperiorI mmunodiversity withMinimalP roteinLeadE ngineering.

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

For further information, please contact:

Citigate Dewe Rogerson
arGEN-X
David Dible
Tim Van Hauwermeiren, MSc, eMBA
Mark Swallow
Chief Executive Officer
Nina Enegren
T: +31 6 122 85 257
T: +44 207 282 2949/2948/1050
E: tim.vh@arGEN-X.com
E: david.dible@citigatedr.co.uk
Debbie Allen, Ph.D.
Senior Director, Business Development
T: +44 7974 979479
E: dallen@arGEN-X.com
Shire - Human Genetic Therapies US
Shire Corporate
Jessica Cotrone
Jessica Mann
T: +1 781 482 9538
T: +44 1256 894280
jcotrone@shire.com
E: jmann@shire.com


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE PLC
01/20 SHIRE : U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465..
01/19 SHIRE : Says US FDA Acknowledges Resubmission Of SHP465 In ADHD
01/19 SHIRE : U.S. FDA Acknowledges Receipt of ...
01/18 SHIRE : *berenberg raises shire price target to 5900 pence - 'buy'
01/17DJSHIRE : Files 8K - Other Events
01/17 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
01/17 SHIRE : Director/PDMR Shareholding
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12 SHIRE : RaNA Acquires Shire's Industry Leading Messenger RNA Platform
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 Pharma bigwigs acknowledge challenges with perceptions of pricing as Trump pr..
01/19 Kala's Eye Focus Could Tempt A Buyer
01/19 FDA receives Shire's resubmitted marketing application for ADHD candidate SHP..
01/18 MERGERS AND ACQUISITIONS IN 2016 : Pause For Breath In A Shifting Market
01/13 Some Humble Advice From An Old Trader
Advertisement
Financials ($)
Sales 2016 11 043 M
EBIT 2016 4 099 M
Net income 2016 1 303 M
Debt 2016 20 557 M
Yield 2016 0,53%
P/E ratio 2016 42,07
P/E ratio 2017 14,23
EV / Sales 2016 6,30x
EV / Sales 2017 4,35x
Capitalization 49 020 M
More Financials
Chart SHIRE PLC
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 76,6 $
Spread / Average Target 41%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
David R. Ginsburg Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC-6.21%49 020
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results